VYNE logo.jpg
VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
May 18, 2022 08:00 ET | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE logo.jpg
VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022 16:05 ET | VYNE Therapeutics Inc.
Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to...
VYNE logo.jpg
VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform
May 10, 2022 08:00 ET | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE logo.jpg
VYNE Therapeutics to Present at LifeSci Partners’ Immunology & Inflammation Symposium on May 10th
May 06, 2022 08:00 ET | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE logo.jpg
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
April 07, 2022 08:00 ET | VYNE Therapeutics Inc.
At week 2, FMX114 demonstrated a statistically significant reduction in both absolute and percent change in ADSI score compared to vehiclePhase 2a safety and efficacy results expected in the second...
VYNE logo.jpg
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis
March 30, 2022 08:00 ET | VYNE Therapeutics Inc.
VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg dosesVYN201 also demonstrated numerically superior results at 1mg/kg and...
VYNE logo.jpg
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update
March 17, 2022 08:00 ET | VYNE Therapeutics Inc.
FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical data in 3 well-established and validated inflammation models BRIDGEWATER,...
VYNE logo.jpg
VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo
March 07, 2022 07:00 ET | VYNE Therapeutics Inc.
VYN201 0.1% and 1% resulted in statistically significant improvement in reducing both melanocyte loss and key inflammatory biomarkers involved in the pathogenesis of vitiligo, an immune-modulated skin...
VYNE logo.jpg
VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference
March 03, 2022 08:00 ET | VYNE Therapeutics Inc.
BRIDGEWATER, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE logo.jpg
VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
January 19, 2022 08:00 ET | VYNE Therapeutics Inc.
Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents Mean Cmax of tofacitinib...